
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc has demonstrated significant progress in its clinical development, as evidenced by positive top-line results reported in June 2023, which bolsters confidence in its pipeline of novel therapeutic candidates for neurodegenerative diseases such as Alzheimer's. The company's current valuation appears attractive based on a net present value (NPV) analysis, suggesting potential for substantial upside from its existing share price. Furthermore, the anticipation of achieving key milestones and the ongoing generation of positive data are expected to serve as crucial catalysts for future stock appreciation.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded earlier estimates of $(0.69), indicating financial deterioration. The company faces substantial risks regarding its product candidates, including the potential inability to demonstrate safety and efficacy in clinical trials, as well as challenges related to regulatory approvals and commercialization. Additionally, the company is exposed to liquidity risks and external market factors, which could adversely impact investor sentiment and the overall viability of its operations in the competitive biopharmaceutical sector.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares